2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, LGL, Hodgkin Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4347 Clonetracker: A statistical framework for inferring clonal architecture and evolution from longitudinal bulk DNA sequencing, evaluated in patients with acute myeloid leukemia, including allogenic HCT recipients

Kaizen Nathani, MS, Raya Mawad, MD2, Winslow Johnson3, Rachel Osborne4, Max Smith5, Jerald Radich, MD6, Cecilia CS Yeung, MD, Professor Pathology7, Elizabeth Florence Krakow, MD,CM, MSc8
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 University of Washington, Seattle, Washington, United States
4 University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States

Introduction
Advances in induction therapy, allogeneic hematopoietic cell transplantation (HCT), and risk-adapted treatment have nearly doubled the 5-year overall survival of adults with acute myeloid leukemia (AML) from ~19% to ~38% over the past two decades. Despite these improvements, relapse remains the leading cause of treatment failure and mortality, affecting ~30% of favourable-risk, ~50% of intermediate-risk, and >80% of adverse-risk patients, including ~43% of patients who undergo allogeneic HCT. Relapse is driven by therapy-resistant clonal evolution and immune escape following HCT, yet current genomic approaches remain limited in accurately reconstructing longitudinal clonal architecture and evolutionary dynamics from sequencing data, such as the next generation sequencing (NGS) panels performed in routine clinical practice. Robust computational frameworks for clonal evolution inference are therefore needed to improve relapse characterization, disease monitoring, and therapeutic decision-making.

Methods
We developed CloneTracker, an end-to-end web-based computational framework for longitudinal clonal evolution analysis, demonstrated here using targeted bulk DNA sequencing data but broadly applicable to other genomic sequencing modalities. CloneTracker integrates variant calling, quality control, annotation, longitudinal variant classification, clonal deconvolution, and phylogenetic reconstruction within a unified workflow. For allogeneic HCT, it provides an ad-hoc module to estimate donor and recipient chimerism using informative germline variants modelled with a beta-binomial framework. Somatic variants are probabilistically assigned to donor- or recipient-derived or shared compartments by integrating chimerism-adjusted longitudinal allele frequency trajectories with read-backed phasing (mutation co-occurrence) to recipient and donor germline markers. Classified variants are subsequently analyzed using PyClone-VI for probabilistic clonal clustering and cellular prevalence estimation, followed by Pairtree for phylogenetic reconstruction of clonal evolution. An interactive web application provides dynamic visualization of longitudinal variant trajectories, clonal phylogenies, and fish plots aligned to clinical treatment and staging data, and quality-control metrics. CloneTracker was evaluated on targeted bulk DNA sequencing data generated on Illumina sequencing platforms from blood or bone marrow aspirates collected longitudinally from seven patients with AML enrolled in an observation study at Fred Hutchinson Cancer Center (FHCC IRB #20714) , including three who underwent allogeneic HCT.

Results
CloneTracker was implemented as a modular, containerized Nextflow-based workflow coupled with an interactive web application for visualization and clinical interpretation. Across seven patients with AML, the framework integrated longitudinal variant profiles with clinical time points to generate quality-controlled mutation trajectories, clonal clusters, phylogenetic trees, and fish plots. In the three allogeneic HCT recipients, germline-variant-based donor chimerism estimates demonstrated >99% concordance with clinical chimerism measurements obtained from CD33-positive blood cells. Integration of chimerism-aware longitudinal modeling with read-backed phasing distinguished donor- and recipient-derived variants and resolved lineage-specific clonal populations across serial samples. The reconstructed clonal trajectories were concordant with clinically documented remission and relapse, identified persistent and emerging subclones, and revealed the temporal dynamics of candidate molecular drivers in relation to transplantation and treatment. In the four patients who did not undergo HCT, CloneTracker identified stable, contracting, and expanding mutation clusters, distinguished persistent founder populations from treatment-responsive and relapse-associated subclones, and reconstructed patient-specific patterns of clonal evolution. Together, these analyses demonstrated the ability of CloneTracker to resolve clinically relevant clonal heterogeneity and connect molecular evolution with longitudinal disease courses.

Conclusion
CloneTracker provides a clinically translatable framework for integrating longitudinal sequencing data with treatment and disease courses to support relapse characterization, disease monitoring, and precision therapeutic decision-making.

Kaizen Nathani, MS: No relevant conflicts of interest to declare.